Literature DB >> 11147323

[Magnetic resonance angiography in inflammatory brain diseases].

S Felber1, A Auer, E Schmutzhard.   

Abstract

In this review, we discuss the diagnostic potential of time of flight (TOF) MRA and contrast enhanced (CE) MRA in inflammatory disorders of the meninges and the brain. Cerebrovascular complications are frequently observed during infectious meningoencepalitis. 3D TOF-MRA and CE-MRA are complementary for the detection of basal intracranial artery stenosis and septic cerebral vein and sinus thrombosis due to secondary vasculitis. MRA reveals stenosis and occlusion as indirect signs of vasculitis, whereas MRI shows the inflammation of the brain and meninges and occasionally the vessel wall, together with the ischemic or hemorrhagic complication. In case of septic emboli MRA can detect peripheral occlusions and "mycotic" aneurysms. For the diagnosis of noninfectious vasculitides of the intracranial vessels, high resolution 3D TOF-MRA is superior to CE-MRA for the detection of multiloculated segmental stenoses. However, there are presently no prospective studies on the sensitivity and specificity of MRA for these indications. Therefore, only positive MRA results can directly influence clinical management. In case of normal MRA, confirmation by catheder angiography may still be required.

Entities:  

Mesh:

Year:  2000        PMID: 11147323     DOI: 10.1007/s001170050880

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

1.  [Magnetic resonance angiography in rheumatology].

Authors:  T A Bley; B Ostendorf; A Scherer; H Kellner; W A Schmidt
Journal:  Z Rheumatol       Date:  2012-07       Impact factor: 1.372

2.  Magnetic resonance angiography in suspected cerebral vasculitis.

Authors:  Philippe Demaerel; Nele De Ruyter; Frederik Maes; Beatrijs Velghe; Guido Wilms
Journal:  Eur Radiol       Date:  2004-02-10       Impact factor: 5.315

Review 3.  Central nervous system vasculitis.

Authors:  Sterling G West
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.